



A STUDY OF LIPID PROFILE AND THYROID HORMONE STATUS IN CHRONIC KIDNEY DISEASE PATIENTS ATTENDING THE DEPARTMENT OF GENERAL MEDICINE, BANKURA SAMMILANI MEDICAL COLLEGE AND HOSPITAL, BANKURA

**Dr. Manoj Kumar Das¹, Dr. Sudip Barua², Dr. Mukesh Kumar³, Dr. Subrata Choudhury^{4*},
Dr Vishal Prakash Giri⁵, Dr Rahul Agarwal⁶, Dr Shakti Bala Dutta⁷,**

¹RMO cum Clinical Tutor, Department Of Nephrology, IPGMER, Kolkata, West Bengal, India

²Assistant Professor, Department Of Pharmacology, College Of Medicine & Sagore Dutta Hospital, Kolkata, West Bengal, India

³Assistant Professor, Department Of Pharmacology, Gouri Devi Institute Of Medical Sciences, Durgapur, West Bengal, India

⁴Assistant Professor, Department Of Pharmacology, Gouri Devi Institute Of Medical Sciences, Durgapur, West Bengal, India

⁵Professor & Head Department of Pharmacology, Pt Ram Prasad Bismil Memorial Medical College Shahjahanpur, UP, India

⁶Associate professor Department of Pharmacology, MSD, ASMC, Bahraich, UP, India

⁷Professor & Head, Department of Pharmacology, Graphic Era Medical University, Dehradun Uttarakhand, India

***Corresponding Author:** Dr. Subrata Choudhury,
Assistant Professor, Department Of Pharmacology, Gouri Devi Institute Of Medical Sciences,
Durgapur, West bengal, India, dr.subratachoudhury@gmail.com

Received date: 10 Jan 2025

Accepted date: 25 Jan 2025

INTRODUCTION

Chronic kidney disease (CKD) encompasses a spectrum of different pathophysiological processes associated with abnormal kidney function and progressive decline in glomerular filtration rate. Now the recently updated classification in which stages of CKD are stratified by estimated GFR and the degree of Albuminuria in order to predict the risk of progression of CKD. Previously CKD has been staged solely by the GFR. However the risk of worsening of the kidney function is closely linked to the amount of albuminuria and so it has been incorporated into the classification¹.

The National Kidney Foundation (NKF) sponsored the Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guidelines in 2002, which described the conceptual model, definition, and classification of CKD (Kidney Disease Outcomes Quality Initiative (K/DOQI), 2002). These guidelines were subsequently adopted with minor modifications by the international guideline group Kidney Disease Improving Global Outcomes (KDIGO) in 2004 (Levey et al., 2005)^{2,3}.

In 2009, KDIGO held a controversies conference to re-examine the CKD definition and classification. Participants at this conference reached a consensus to retain the 2002 KDOQI definition of CKD, but recommended including the cause of CKD and the level of albuminuria in the revised classification

system (Levey et al., 2011)^{2,4}. Based on these recommendations, KDIGO recently updated the 2002 KDOQI guidelines in 2012 (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013). CKD is defined as the presence of kidney damage or GFR < 60 mL/min/1.73 m² (GFR in mL/min/1.73 m² may be converted to mL/s/1.73 m² by multiplying by 0.01667) for ≥ 3 months, irrespective of cause (Kidney Disease Outcomes Quality Initiative (K/DOQI), 2002; Levey et al., 2005).²

CKD is classified based on Cause, GFR category (G1-G5) and Albuminuria category (A1-A3), abbreviated as CGA.⁵

GFR categories (mL/min/ 1.73 m²). Description and range⁵

G1	Normal or high	≥90
G2	Mildly decreased	60-89
G3a	Mild to moderately decreased	45-59
G3b	Moderate to severely decreased	30-44
G4	Severely decreased	15-29
G5	Kidney failure	<15

Persistent albuminuria categories. Description and range (By albumin-creatinine ratio – ACR)⁵

A1	A2	A3
Normal to mildly increased	Moderately increased	Severely increased
<30 mg/g <3 mg/mmol	30-300 mg/g 3-30 mg/mmol	>300 mg/g >30 mg/mmol

Chronic kidney disease (CKD) is becoming a serious health problem. The number of people with impaired renal function is rapidly rising, especially in industrialized countries⁶. The crude and age adjusted end stage renal disease (ESRD) incidences in India have been estimated to be 151 and 232 per million population, respectively.⁷

In India, Mani^{8,9} reported a prevalence of CKD of 1.1% among a rural population of 25,000 who were subjects of a universal screening program in which serum creatinine level was measured only in those with hypertension or proteinuria. Agarwal and colleagues^{8,10} screened 4700 adults in an urban community and found a point prevalence of 7852 per million individuals with a serum creatinine level greater than 1.8 mg/dL. These figures must be interpreted with caution because of the wide variations in the definition of CKD, methodology, and sampled population.⁸

Reports suggest that progression of CKD is associated with having a number of complications, including dyslipidemia, thyroid dysfunction and CVD.^{11,12} Of the multiple lipid abnormalities in patients on maintenance HD, low high-density lipoprotein (HDL) and elevated lipoprotein (a) [Lp(a)] are key predictors of cardiovascular disease.⁸ Lipid abnormalities are common in patients with CKD. In several studies, dyslipidemia has been identified as both a susceptibility risk factor and a progression risk factor for CKD. Dyslipidaemia is a major risk factor for coronary heart disease. Several factors contribute to the development of dyslipidemia associated with chronic renal impairment. Patients with CKD have a reduction in the activity of lipoprotein lipase and hepatic triglyceride lipase. This interferes with uptake of triglyceride rich, apolipoprotein B containing lipoproteins by the liver and in peripheral tissue, yielding increased circulation of these atherogenic lipoproteins¹¹. Progression of CKD is accompanied by the development of specific alterations of the lipoprotein metabolism¹². Reports show that mortality due to CVD was 10–30 times higher in dialysis patients than in the general population¹³. Abnormalities in lipid metabolism occur in all stages of CKD. In CKD beyond stage 3, the characteristic lipid profile is accumulation of very low density

lipoprotein (VLDL), intermediate density lipoprotein (IDL), elevated triglyceride (TG), low high density lipoproteins (HDL)^{13,14} and elevated LDL/HDL ratio^{15,16}

The pattern of dyslipidaemia depends on the stage of CKD, dialysis and transplantation, proteinuria, drug therapy, and primary disease (e.g. diabetes). It is simplest, therefore, to refer to dyslipidaemia, rather than hyperlipidaemia, as cholesterol concentrations may not be raised.²

The characteristic features of dyslipidaemia associated with CKD are elevated triglycerides (TGs), reduced high-density lipoprotein cholesterol (HDL-C), and increased intermediate-density lipoprotein cholesterol (IDL-C) (Kidney Disease Outcomes Quality Initiative (K/DOQI) Group 2003; Prichard, 2003; Jardine et al., 2008. These are associated with qualitative changes in lipoproteins, including an excess of TG-rich, immature, atherogenic lipoproteins (Vaziri, 2006).^{17,18,19,20}

All these defects contribute to the overall pattern of dyslipidaemia—the pattern reflecting the effects of low GFR and proteinuria. The key features are an increase in TG-rich, immature particles; with elevated TGs, reduced HDL-C and increased IDL-C rather than the increase in LDL-C that is associated with increased risk of CVD in other populations.^{16,17,20}

It is also seen that Moorhead and colleagues advanced the hypothesis that abnormalities in lipid metabolism may contribute to the progression of CKD.^{8,21,22} They proposed that urinary losses of albumin and lipoprotein lipase activators result in an increase in circulating LDLs, which in turn bind to the glomerular basement membrane further impairing its permeability; filtered lipoproteins accumulate in the mesangium, stimulating extracellular matrix synthesis and mesangial cell proliferation; filtered LDL is taken up and metabolized by the tubules, leading to cell injury and interstitial disease. Several lines of experimental evidence confirm the association between dyslipidemia and renal injury.^{21,22}

Several epidemiological studies found a strong association between CKD progression and dyslipidemia. In the MDRD study, low serum HDL cholesterol was found to be an independent predictor of more rapid rates of decline in GFR.^{21,23} Elevated total cholesterol, LDL-cholesterol, and apolipoprotein B have been found to correlate strongly with GFR decline in CKD patients.^{21,24} Hypercholesterolemia was shown to be a predictor of loss of renal function in type 1 and type 2 diabetics.^{21,25} Among non-diabetic patients CKD advanced more rapidly in patients with hypercholesterolemia and hypertriglyceridemia, independent of blood pressure control.^{21,26}

Most endocrine systems are tightly regulated in a multiple-level feedback loop to attain circulating hormone levels to maintain adequate amount of hormone level. Reduced renal function and uremia can interfere with this feedback system and cause significant derangement of circulating hormonal level^{26,27}.

Thyroid hormones and renal systems are interlinked in a very complex manner.^{28,29} The kidney normally plays an important role in the metabolism, degradation and excretion of thyroid hormones. CKD affects the hypothalamus pituitary thyroid axis, including low circulating thyroid hormone levels, altered peripheral hormone metabolism, insufficient binding to carrier proteins, reduced tissue thyroid hormone content and altered iodine storage in the thyroid gland. Thus in CKD thyroid hormone metabolism is impaired^{29,30}. It also alters the 'Milieu interior' that affects every system in the body. One such system in the body is thyroid hormonal system. Kidney is closely related to thyroid in the fact that it is the only other organ that competes with iodide clearance^{31,32}. Thus, in CKD, thyroid hormone metabolism is impaired. Thyroid hormones (TH) are necessary for growth and development of the kidney and for the maintenance of water and electrolyte homeostasis. On the other hand, kidney is involved in the metabolism and elimination of TH. Both hypothyroidism and hyperthyroidism are accompanied by remarkable alterations in the metabolism of water and electrolyte, as well as in cardiovascular function. All these effects generate changes in water and

electrolyte kidney management³². Thyroid dysfunction acquires special characteristics in those patients with advanced kidney disease^{31,33,34}. On the other hand, the different treatments used in the management of patients with kidney and thyroid diseases may be accompanied by changes or adverse events that affect thyroid and kidney function respectively. Epidemiological data showed that CKD has increased risk of hypothyroidism. In CKD, hypothyroidism causes increased cardiac morbidity^{32,34}.

AIMS AND OBJECTIVES

AIMS

To find out the prevalence of lipid and thyroid disorders in patients of chronic kidney disease.

OBJECTIVES

- 1) To assess lipid profile in chronic kidney disease patients.
- 2) To find out serum levels of different hormones related to thyroid function (T₃, T₄, TSH) in chronic kidney patients.
- 3) To study the correlation of thyroid hormone status with derangement of kidney function.
- 4) To study the correlation of lipid profile with derangement kidney function.

MATERIALS AND METHODS

Study area: Department of General Medicine, BSMCH, Bankura

Study period: One year

Study population: Patients admitted (indoor) and attending outpatient department of BSMCH.

Inclusion Criteria

All patient with age > 18 yr with proved chronic kidney disease according to NKF-KDOQI guidelines. CKD will be defined on the basis of National Kidney Foundation guidelines of having an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.732 m² for more than 3 months. The Modification of Diet in Renal Disease study (MDRD) equation will be used to calculate eGFR.

Exclusion Criteria

- Hypopituitarism
- Secondary hypothyroidism due to ICSOL and radiation therapy
- Patient on thyroid or antithyroid medication and anti lipid medications.
- Previously undergone thyroid surgery
- Acute on chronic kidney disease
- Any febrile episode during the evaluation

Sample size: $N = (Z^2 pq) / L^2$, where $Z = 1.96$ at 5% precision, p = prevalence of thyroid dysfunction, $q = (100 - p)$, L = allowable error.

Now, $N = (3.84 \times 9 \times 91) / 5^2$ [Assuming $p = 9\%$ & $L = 5$ (absolute)]
 $= 125.79 = 126$ (Approx.).

Revised sample size, $N_s = N \times FPC$ (Finite population correction)

$N_s = N \times FPC = N \times \sqrt{\{(N_p - N) / (N_p - 1)\}} = 126 \times 0.79 = 99.5 \approx 100$ [where, N_p = target finite population; here it will be 600].

Sampling design: Systemic Random Sample will be taken. There will be minimum 28 (7x4) weeks for data collection. Number of patients will have to selected per clinic day = $100 / 28 = 3.57 = 4$. These four patients will be selected from the 20 patients attending daily. Systemic Random Sampling technique will be undertaken for selecting study subjects. So, every 20/4 = 5th patient will be approached. The starting will be done unbiasedly, using simple random sampling method involving those who will be present at the time of starting sampling

Study Type: Descriptive hospital based study.

Study Design: Cross sectional study.

Study Variables:

Socio-demographic variables:

Age, Sex, Residence, Occupation, Marital status, Family income, Co-morbidity

Biochemical parameter

- Serum creatinine, urea, sodium, potassium

- Serum T₃, T₄, TSH

- Lipid profile- Total Cholesterol, Low density lipoprotein, High density lipoprotein, Triglyceride, Very low density lipoprotein

Radiological study

-Ultrasonography of kidney, ureter, bladder system

Study tools:

1. Predesigned & pretested Questionnaire.
2. Equipments for clinical examination including anthropometry (weighing machine, sphygmomanometer, measuring tape).
3. Materials needed for withdrawal blood from patients: cotton & spirit, disposable syringe with needle, hub-cutter, gloves, tourniquet, vials (clotted, fluoride), eppendorfs.
4. Sterile container for collection of urine.
5. Laboratory instruments: The machines are already existed in the laboratory & will be used for the present study-
 - a. Semi automated clinical chemistry analyzer.
 - b. ELISA reader.
 - c. Centrifuge machine.
 - d. Micropipettes, beaker, centrifuge tubes, funnel, measuring cylinder, test tubes, test tube rack, dispensing bottle.
6. USG machine available in Radiology department.
7. Reagents and kits for estimation of serum T₃, T₄, TSH, urea, creatinine and lipid profile.

Study technique: Patient attending outdoor and admitted in BSMC&H Medicine dept are randomly selected according to inclusion and exclusion criteria and subjected to detailed history taking, clinical, haematological, biochemical and radiological examination.

Procedure of data collection: Subjects will be selected according to the exclusion & inclusion criteria. The patients will be taken from the outpatient department as well as the Inpatient department of General Medicine.

Method of data analysis: Data will be codified, compiled & tabulated in MS Excel spread sheet and summarised using mean, median, proportions, standard deviation, range etc. Tables, charts, diagrams etc will be prepared for describing data. Different statistical tests like Chi-square, Independent t-test, ANOVA, Pearson's/Spearman's correlation coefficients etc. will be done as per necessity. Statistical software [Statistical Package for Social Sciences (SPSS)- free version] will be utilised, if required

Ethical consideration: This study will be conducted only after obtaining proper written ethical permission. From the Ethics Committee of BSMC&H and approval from West Bengal University of Health Sciences. Written informed consent will be taken from every study subject or from their legal representative.

Additional Resources

- Human resources:
- Financial support: No additional financial support is required as the procedures will be done in the respective departments in the Institute

Table 1: Distribution of patients according to Age and Sex (n=100)

Age (years)	Male		Female		Total	
	No	%	No	%	No	%
≤ 30	12	75.0	4	25.0	16	100.0
31 – 60	41	66.1	21	33.9	62	100.0
> 60	18	82.8	4	18.2	22	100.0
Total	71	71.0	29	29.0	100	100.0
Mean age 50.56, SD 13.72						

It is observed from the above table that the maximum number of study subjects were male(71%) and 29% were female. Highest proportion of participants found in age group of 31-60 years of age, of which 66.1% were male (41 patients) and rest were female (34%, 21 patients).Total 62 patients in this age group.

Among the patients less than or equal to 30 years of age male patients were 12 in number (75%) and female patients were 4 in number (25%).

Above 60 years of age 82% (18 in number) were male and 18% (4 in number) were female. Mean age is 50.56 and SD 13.72




Fig: Bar diagram showing age and sex distribution of study participants (n = 100)

Table 2: Distribution of patients according to staging of CKD (n=100)

	Range of eGFR (ml/min)	No	%	Mean of eGFR (ml/min)	SD of eGFR (ml/min)
CKD- III	30-59	9	9.0	35.54	3.49
CKD- IV	15-29	25	25.0	19.35	3.55
CKD- V	<15	66	66.0	8.12	3.79

In this table it has been showed that maximum number of participants were within CKD stage V (66%). Minimum number of patients were in CKD III (9%). CKD-IV stage had only 25% of participants. Mean eGFR and SD of CKD stage III,IV,V are 35.54±3.49, 19.35±3.55, 8.12±3.79




Fig: Pie diagram showing stages of CKD among study participants (n = 100)

Table 3 : Mean and SD of urea and creatinine levels in study subjects (n = 100)

	Mean	SD
Urea (mg/dl)	107.34	28.69
Creatinine (mg/dl)	6.68	4.03

It is observed from above table Mean and SD of urea and creatinine are 107.34 ± 28.69 , 6.68 ± 4.03




Fig: Scatter plot and trendline showing urea and creatinine values among study participants (n = 100)

Table 4: Distribution of patients according to Sonographic finding and level of urea (n=100)

	No	%	Level of urea (mg%)		t = 2.78 DF = 98 p = 0.007
			Mean	SD	
BLCK (Bilateral Contracted Kidney)	84	84.0	110.7	29.1	
CMDL (Cortico-Medullary Differentiation Lost)	16	16.0	89.7	18.6	
Total	100	100.0			

From the above table highest number of patients were found to have bilateral contracted kidney disease (BLCK) that was 84% and rest was 16 %. Mean and SD of urea is 110.7 ± 29.1 in case of BLCK and 89.7 ± 18.6 in case of CMDL . $p=0.007$ and it is significant.




Fig: Pie diagram showing sonographic findings of CKD among study participants (n = 100)

Table 5: Distribution of patients according to Sonographic finding and level of creatinine (n=100)

	No	%	Level of creatinine		t = 1.59 DF = 98 p = 0.115
			Mean (mg%)	SD (mg%)	
BLCK (Bilateral Contracted Kidney)	84	84.0	6.95	3.92	
CMDL (Cortico-Medullary Differentiation Lost)	16	16.0	5.22	4.39	
Total	100	100.0			

From the above table it has been shown mean and SD of creatinine in BLCK is 6.95 ± 3.92 , and in CMDL it is 5.22 ± 4.39 . $p=0.115$ it is not significant.

Table 6: Distribution of patients according to CKD stage and level of total cholesterol(n=100)

	High total cholesterol		Normal total cholesterol		Chi square 0.1112 df 2 p 0.946
	No	%	No	%	
CKD III	4	44.44%	5	55.56%	
CKD IV	12	48.00%	13	52.00%	
CKD V	33	50.00%	33	50.00%	

It has been shown for the table maximum number of patients in CKD-V stage (50%), followed by in CKD stage IV (48%) and in CKD III (44%).




Fig:Compound Bar diagram showing stages of CKD and level of cholesterol among study participants (n = 100)




Fig:Compound Bar diagram showing stages of CKD and level of Triglyceride among study participants (n = 100)

Table 7 : Level of Cholesterol according to sex (n=100)

	No	%	Level of Cholesterol		t =-.08 DF =98 p =0.437
			Mean (mg%)	SD (mg%)	
Male	71	71	197.88	77.11	
Female	29	29	184.42	81.03	
Total					

This table shows mean and SD of cholesterol in male and female patients are 197.88 ± 77.11 and 184.42 ± 81.03 . $p = 0.437$

Table 8 :Level of Triglyceride according to sex (n=100)

	No	%	Level of TG		t = -0.50 DF = 98 p = 0.619
			Mean (mg%)	SD (mg%)	
Male	71		122.02	45.9	
Female	29		117.05	43.55	
Total	100	100.0			

Mean and SD of triglyceride are 122.02±45.9 for male and 117.05±43.55 in case of female.p=0.619

Table 9: Distribution of patients according to CKD staging and Triglyceride level (n=100)

	High Triglyceride		Normal Triglyceride		Chi square 0.07 DF 2 P value 0.9653
	No	%	No	%	
CKD III	2	22.2	7	78.8	
CKD IV	6	24.0	19	76.0	
CKD V	17	25.8	49	74.2	
TOTAL	25	25.0	75	75.0	

From the above table it has been found that total 25% of patients had high Triglyceride (TG) level. Proportion of high TG level were 22.2%, 24.0% and 25.8% among patients in stage III, stage IV and stage V respectively. However this difference was not significant as p = 0.965




Fig:Compound Bar diagram showing stages of CKD and level of Triglyceride among study participants (n = 100)

Table 10: Distribution of patients according to CKD staging and HDL (n=100)

	Low HDL		Normal HDL		Chi square 2.345 DF 2 P value 0.3096
	No	%	No	%	
CKD III	6	54.6	5	45.6	
CKD IV	22	88.0	3	12.0	
CKD V	56	84.8	10	15.2	
TOTAL	84	84.0	18	18.0	

It has been shown that among all 84 patients having low HDL cholesterol, maximum percentage of patients are in stage CKD-IV (88%), then in stage CKD-V (84.8%), and 6 patients are in CKD-III staging (54.6%).

Rest of the patients (18%) out of 100 total had normal HDL cholesterol. However this difference was not significant as $p = 0.309$




Fig:Compound Bar diagram showing stages of CKD and level of HDL among study participants (n = 100)

Table 11 : Level of HDL according to sex (n=100)

	No	%	Level of HDL		t = -0.53 DF = 98 p = 0.596
			Mean (mg%)	SD (mg%)	
Male	71		34.14	7.04	
Female	29		33.34	5.93	
Total	100	100.0			

Mean and SD of HDL cholesterol is 34.14 ± 7.04 in male and 33.34 ± 5.93 in female. $p = 0.596$

Table 12 : Distribution of patients according to CKD staging and LDL (n=100)

	High LDL		Normal LDL		Total	Chi square 1.15 DF 2 P value 0.562591
	No	%	No	%		
CKD III	4	44.4	5	55.6	9	
CKD IV	7	28.0	18	72.0	25	
CKD V	18	27.3	48	72.7	66	
TOTAL	29	29.0	75	75.0	100	

From the above table it has been found that total 29% of patients had high LDL level. Proportion of high LDL level were 44.4%, 28.0% and 27.3% among patients in stage III, stage IV and stage V respectively. However this difference was not significant as $p = 0.562$




Fig:Compound Bar diagram showing stages of CKD and level of LDL among study participants (n = 100)

Table 13 : Level of LDL according to sex (n=100)

	No	%	Level of LDL		t = 1.2 DF = 98 p = 0.234
			Mean (mg%)	SD (mg%)	
Male	71		81.09	24.79	
Female	29		88.34	33.23	
Total	100	100.0			

Mean and SD of LDL cholesterol is 81.09 ± 24.79 in male and 88.34 ± 33.23 in female patients. $P = 0.234$ is not significant.

Table 14: Distribution of patients according to CKD staging and VLDL (n=100)

	High VLDL		Normal VLDL		Total	Chi square 0.38 DF 2 p value 0.827
	No	%	No	%		
CKD III	4	44.4	5	55.56	9	
CKD IV	14	56.0	11	44	25	
CKD V	36	54.6	30	30	66	
TOTAL	54	54.0	46	46.0	100	

It has been shown that among all 54 patients having high VLDL cholesterol, maximum 14 patients are in stage CKD-IV (56%), then in stage CKD-V 36 patients (54.6%), and 4 patients are in CKD-III staging (44.4%).

Rest of the patients (46%) out of 100 total had normal VLDL cholesterol. However this difference was not significant as $p = 0.827$




Fig:Compound Bar diagram showing stages of CKD and level of VLDL among study participants (n = 100)

Table 15 : Level of VLDL according to sex (n=100)

	No	%	Level of VLDL		t = 1.57 DF = 98 p = 0.119
			Mean (mg%)	SD (mg%)	
Male	71		30.44	6.8	
Female	29		34.67	20.1	
Total	100	100.0			

Mean and SD of VLDL is 30.44±6.8 in male and 34.67±20.1 in female patients. P= 0.119 is not significant.

Table 16 :Mean and SD of the lipid profile of study subjects

	Mean (mg/dl)	SD
Cholesterol	193.97	78.1
Triglyceride	120.58	45.07
HDL	33.91	6.72
LDL	83.20	27.52
VLDL	31.67	12.27

From the above table it was found that out of 100 patients studied mean value of cholesterol, triglyceride, HDL, LDL, VLDL were 193.97(mg/dl), 120.58(mg/dl), 33.9(mg/dl), 83.20(mg/dl), 31.67(mg/dl) respectively.

Standard deviation were 78.1, 45.0, 6.72, 27.52, 12.27 for cholesterol, triglyceride, HDL, LDL, VLDL respectively.

Table 17 : Distribution of patients according to Thyroid abnormalities (n = 100)

	No	%
Low T ₃ syndrome	13	13.0
Low T ₄ syndrome	4	4.0
Low T ₃ & T ₄ syndrome	5	5.0
Subclinical hypothyroid	15	15.0
Overt hypothyroid	9	9.0
Euthyroid	59	59.0
Total	100	100.0

It has been found that 41% of patients showed some or other thyroid abnormalities and among them highest number of patients had sub-clinical hypothyroidism (15%). Second highest was CKD with low T_3 syndrome. Low T_3 & low T_4 was found amongst 5% of all participants. Lowest number of patients had CKD with low T_4 and 9% of the patients were suffering from overt hypothyroidism.

Table 18 : Distribution of patients according to CKD staging and T_3 status (n=100)

	Low T_3		Normal T_3		Total	Chi square 3.30 df 2 p=0.1916
	No	%	No	%		
CKD III	5	55.56	4	44.44	9	
CKD IV	6	24.00	19	76.00	25	
CKD V	26	39.39	40	60.61	66	
TOTAL	37	37.0	63	63.0		

Proportion of Low T_3 level was highest in patients of CKD-III stage (55.6%), followed by CKD-IV patients (39.4%). Only 6 patients of CKD-IV staging had low T_3 status (24.0%). This apparent difference was not found to be significant as $p = 0.192$.




Fig:Compound Bar diagram showing stages of CKD and level of T_3 among study participants (n = 100)

Table 19 : Distribution of patients according to CKD staging and T_4 status (n=100)

	Low T_4		Normal T_4		Chi square 0.08 df 2 p 0.961
	No	%	No	%	
CKD III	2	22.2	7	77.8	
CKD IV	5	20.0	20	80.0	
CKD V	15	22.7	51	77.3	
TOTAL	22	22.0	78	78.0	

From the above table it had been found that proportion of Low T_4 status is highest in CKD-V stage (22.73%). 22.2% of all CKD-III patients and 20% of all CKD-IV patients showed low T_4 status. So total 22 patients out of 100 patients had CKD with low T_4 hormone level and rest 78 participants had only CKD with normal thyroid hormone status. There was no statistically significant difference ($p = 0.961$).




Fig:Compound Bar diagram showing stages of CKD and level of T4 among study participants (n = 100)

Table 20 : Distribution of patients according to CKD staging and TSH status (n=100)

	High TSH		Normal TSH		Chi square DF 2 P value 0.5815
	No	%	No	%	
CKD III	5	55.6	4	44.4	
CKD IV	9	36.0	16	64.0	
CKD V	26	39.4	40	60.6	
TOTAL	40	40.0	60	60.0	

From the above table it had been found that proportion of high TSH status is highest in CKD-III stage (55.6%). 36.0% of all CKD-IV patients and 39.4% of all CKD-V patients showed high TSH status. Overall 40.0% of all patients reported to have high TSH. The difference was not found to be of statistical significance ($p = 0.581$)




Fig:Compound Bar diagram showing stages of CKD and level of TSH among study participants (n = 100)

Table 21 :Mean and SD of the Thyroid value of study subjects

	Mean	SD
T ₃ (ng/ml)	0.67	0.46
T ₄ (μg/dl)	5.77	2.04
TSH (μIU/ml)	6.98	6.24

It has been showed from above table that calculated mean for T₃, T₄, TSH are 0.67 (ng/ml),5.77(μg/dl),6.98(μIU/ml) respectively.Standard deviation for T₃, T₄, TSH are0.46,2.04,6.24 respectively.

Table 22 : Level of T₃ according to sex (n=100)

	No	%	Level of LDL		t = 0.14 DF = 98 p = 0.889
			Mean (ng%)	SD (ng%)	
Male	71		0.66	0.43	
Female	29		0.68	0.54	
Total	100	100.0			

From the above table it has been shown Mean and SD of T₃ in male patients are 0.66±0.43 and 0.68±0.54 in female. p=0.889 is not significant.

Table 23 : Level of T₄ according to sex (n=100)

	No	%	Level of T ₄		t = -.06 DF = 98 p = 0.949
			Mean (μg%)	SD (μg%)	
Male	71		5.77	2.19	
Female	29		5.75	1.66	
Total	100	100.0			

From the above table it has been shown Mean and SD of T₄ in male patients are 0.5.77±2.19 and 5.75±1.66 in female. p=0.949 is not significant.

Table 24 : Level of TSH according to sex (n=100)

	No	%	Level of TSH		t = -.082 DF = 98 p = 0.416
			Mean (μIU/ml)	SD (μIU/ml)	
Male	71		6.65	5.51	
Female	29		7.78	1.66	
Total	100	100.0			

From the above table it has been shown Mean and SD of TSH in male patients are 6.65±5.51 and 7.78±1.66 in female. p=0.416 is not significant.

Table 1: Distribution of patients according to Age and Sex (n=100)

Age (years)	Male		Female		Total	
	No	%	No	%	No	%
≤ 30	12	75.0	4	25.0	16	100.0
31 – 60	41	66.1	21	33.9	62	100.0
> 60	18	82.8	4	18.2	22	100.0
Total	71	71.0	29	29.0	100	100.0
Mean age 50.56, SD 13.72						

It is observed from the above table that the maximum number of study subjects were male (71%) and 29% were female. Highest proportion of participants found in age group of 31-60 years of age, of which 66.1% were male (41 patients) and rest were female (34%, 21 patients). Total 62 patients in this age group.

Among the patients less than or equal to 30 years of age male patients were 12 in number (75%) and female patients were 4 in number (25%).

Above 60 years of age 82% (18 in number) were male and 18% (4 in number) were female. Mean age is 50.56 and SD 13.72

DISCUSSION

The present topic “a study of lipid profile and thyroid hormone status in chronic kidney disease patients attending the department of general medicine, Bankura Sammilani Medical College and Hospital, Bankura”

A descriptive, cross-sectional, hospital based study conducted over a period of one year from 1st July 2016 to 30th June 2017 among the patients suffering from chronic kidney disease attending in-patient and out-patient department of Medicine, Bankura Sammilani Medical College and Hospital (BSMC&H), Bankura. A total of 100 patients presenting with features of chronic kidney disease were studied. The objective of the proposed study is to find out the occurrence of lipid & thyroid disorders in patients of chronic kidney disease. Various studies were conducted about dyslipidaemia and thyroid dysfunction in CKD patients and had been shown different results.

The study started after obtaining ethical clearance of institutional ethics committee of BSMC&H and approval of the West Bengal University of Health Sciences Kolkata. Before beginning the sample collection, written informed consent obtained from each patient who will agree to take part in the study.

The results and observation of the study are discussed below.

Table 1 reveals that the mean age of the population of the study is 50.6 years and SD is 13.7. It is observed from the above table that the maximum numbers of study subjects were male 71% and 29% were female. Highest proportion of participants found in age group of 31-60 years of age, of which 66.1% were male (41 patients) and rest were female (34%, 21 patients). Total 62 patients in this age group. Among the patients less than or equal to 30 years of age male patients were 12 in number (75%) and female patients were 4 in number (25%). Above 60 years of age 82% (18 in number) were male and 18% (4 in numbers) were female. This is in agreement with the findings of Saharet al³⁵ who reported a mean age of 52.50 ± 14.96 and in study of Ganta et al³⁶ mean age was 55.14 ± 12.27 . In some study done by Szu-Chia Chen et al³⁷ found to have a older age group participants (mean age was 63.56). Two other Indian study done by Rajapurkar M.M. et al³⁸ (50.1 ± 14.6) & Modi G.K. et al³⁹ (47 years) has closer value to our study. In our study majority are male participants (71%) like the study of Ganta et al³⁶ where 63.57% are male patients.

In table no 2 & 3 highest percentage of patients are in CKD stage V (66%) and mean eGFR is 12.6 ± 8.7 . This trend is also found in the study of Ganta et al³⁶ and Swaminathan et al⁴⁰ where maximum no. of patients are in CKD-V. Szu Chia et al⁴⁰ and Saroj et al⁴¹ found a slightly in high range of eGFR i.e. 24.76, 28.2 respectively. Different studies show variation in range of urea and creatinine. The range of mean urea of our study (107.34) is similar to Saroj et al⁴¹ (106.3) but Rashmi et al⁴² (mean urea 137.75) and Sahar et al³⁵ (mean urea 188.25) have found high mean urea than our study and Raju et al⁴⁴ had a lower range of finding (90.46).

In Table no. 4 ultra sonographic findings revealed that majority of participants had bilateral contracted kidney (84%) than loss of cortico-medullary differentiation (16%) and there was a significant difference in level of urea ($p=0.0007$). As CMDL occurs earlier than BLCK in sonographic findings so it may reflect in level of urea which is higher in BLCK stage when the damage in kidney is more than CMDL stage. This trends was exist in value of creatinine also but no significant difference ($p=0.115$).

Several studies on lipid profile in CKD patients observed hypertriglyceridemia, hypercholesterolemia, increased LDL and decreased HDL [10-15]. In general, the prevalence of hyperlipidemia increases as renal function declines, with the degree of hypertriglyceridemia and elevation of LDL cholesterol being proportional to the severity of renal impairment.[4] CKD affects lipoprotein metabolism, leading to hypercholesterolemia, hypertriglyceridemia and excess LDL cholesterol.[26] Many studies have reported rise in level of lipid parameters and dyslipidemia prevalence in patients with CKD, which may further assist in renal disease progression.[10] In our study we found mainly hypercholesterolemia, low HDL, high VLDL. High triglyceride and LDL value also exist but not as profound as other lipid fractions.

According to table 6 over all hypercholesterolemia was observed in our study is 49%, male had much higher percentage (71%) and there was a increasing trend of hypercholesterolemia from CKD III to CKD V (CKDIII has 44.44% hypercholesterolemia, CKD IV 48%, CKD V 50%) though not significant ($p=0.946$). Mean cholesterol of our study was 193.97 ± 78.1 similar to saroj et al⁴¹ (191.9 ± 31.7). Different study showed hypercholesterolemia like Saroj et al⁴¹ (34.4%), Ghanta et al³⁶ (22.86%), Poudel B et al⁴⁵ (33.75%). Few studies like Rashmiet al⁴³ and Gerald Appel⁴⁴ found even low level of cholesterol in CKD.

In table 8 in our study 25% of cases had hypertriglyceridemia. Mean is 120.58 ± 45.07 . Study done by Rashmiet al⁴³ had mean triglyceride of 163.87 and Raju et al⁴⁶ had much higher value 209.80. Michel et al¹⁷ study found similar triglyceride value to our study (124). Ghanta et al³⁶ and Khalidah et al⁴⁴ had much lower mean value of triglyceride 116 & 113.8 respectively.

Table 10 showed 84% of study subjects had low level of HDL of mean value 33.91 ± 6.72 and similar mean value of HDL was found in the study of Rashmi et al⁴² (31.75) , Raju et al⁴³ (35.28), Khalidah et al⁴⁴ (33.68). Some of studies done by VeerenGanta et al³⁶ and Saroj et al⁴¹ had found much higher mean value of HDL 43.15 ± 16 , 42.1 ± 5.9 . In our study 84% of participants had high HDL and highest number of patients (56 patients) having high HDL value are in CKD stage V though $p=0.3096$ is not but there was a tendency of increasing HDL as CKD is worsening. High HDL cholesterol was found in 22.86% of patients in study done by VeerenGanta et al³⁶, Saroj K et al⁴¹ study also showed 34.1% had high HDL value. In a comparative study done by Rashmiet al⁴² between CKD patients and control group, there was decreased HDL seen in CKD group. The significant decrease of HDL-C in CKD can be attributed to

- (i) Decreased levels of apolipoproteins AI and AII; the main protein constituents of HDL [34].
- (ii) Diminished activity of LCAT; the enzyme responsible for the esterification of free cholesterol in HDL particles [35].
- (iii) Increased activity of Cholesteryl Ester Transfer Protein (CETP) that facilitates the transfer of cholesterol esters from HDL to triglyceride-rich lipoproteins [36].

All these factors combinedly act to reduce the serum concentration of HDL-C.

From table 12, high LDL value has been found in 29% of cases and mean value is 83.20 ± 27.52 . Mean value of our study is much closer to study done by VeerenGanta et al³⁶ (83.81 ± 34.76), Khalidah et al⁴⁵ (87.44 ± 24.30). Few studies like Raju et al⁴⁶ (105.22 ± 26.15) , Saroj et al⁴¹ (103.6 ± 28.1), Sahar et al³⁵ (139.60 ± 6.26) found higher value than our study. Rashmi et al⁴² study did not reveal any difference between CKD and control group , even they found lower mean value of LDL in CKD group (63.23 ± 46.47). Percentage wise high LDL value was found in study by VeernerGanta et al³⁶ (12%) which is lower than our study and Poudel et al⁴⁶ found higher percentage 38.03%.

Elevated plasma LDL cholesterol is common in nephrotic syndrome but it is not a typical feature of patients with advanced CKD, especially those who are on hemodialysis. In CKD patients, the hepatic LDL receptor gene expression is not altered until there is significant glomerulosclerosis or heavy proteinuria [9].

Table 14 showed that there was a trend of high VLDL from CKD III to CKD V. In our study 54% of patients have high VLDL level among all cases. Mean value of VLDL in our study is 31.67 ± 12.27 . Similar findings have been found in study done by Rashmi et al⁴² (32.57 ± 13.55) and Raju et al⁴⁷ (41.96 ± 6.48). The factors which explain the increase in serum VLDL are

(i) the increased activity of CETP which increases transfer of cholesterol ester to VLDL and promotes more VLDL formation [36].

(ii) Increased apo C-III, which is an LPL inhibitor inhibiting the degradation of VLDL [23]. These factors increase the level of serum VLDL-C in CKD patients.

The present study identifies thyroid dysfunction and dyslipidemia as a common disorder in CKD patients. From table 17 to table 24, it had been shown that thyroid dysfunction was found in (41) % CKD patients, the most common being subclinical hypothyroidism (15%), followed by low T₃ syndrome (13%), overt hypothyroidism (9%), low T₃ and low T₄ syndrome together (5%), only low T₄ syndrome (4 %). Study by Lo et al²³ found that the prevalence of hypothyroidism increased with lower levels of GFR (in units of mL/min/1.73 m²), occurring in 5.4 % of subjects with GFR greater than or equal to 90, 10.9 % with GFR 60–89, 20.4 % with GFR 45–59, 23.0 % with GFR 30–44, and 23.1 % with GFR < 30 ($p < 0.001$ for trend). They reported that 56 % of hypothyroidism cases were subclinical. Studies of Saroj et al⁴¹ and Song et al⁴⁸ also found an increasing trend of low T₃ as GFR decreases.

In general population, prevalence of subclinical hypothyroidism is 4-10%. Our study is similar to study done by Saroj et al⁴¹ who found thyroid dysfunction 38.6%, subclinical hypothyroidism 27.2%, overt hypothyroidism 8.1%.

In our study, over all low T₃ value among all CKD patients was found in 37% of patients; 5 cases are in CKD III, 6 patients in CKD IV, and 26 cases in CKD V. Over all low T₄ value was found 22% of patients; 2 cases in CKD III, 5 patients in CKD IV, and 15 cases in CKD V. High TSH value was found in out of 100 participants was 5 cases in CKD III, 9 cases in CKD IV, 26 cases in CKD V; total 40% cases have high TSH value. So there was a trend of increasing TSH and low T₄, T₃ value from CKD stage III to CKD stage V.

Studies done by Jingxian et al⁴⁹ and Swaminathan et al³⁹ found a lower percentage of subclinical hypothyroidism (4.7%) & (8%) respectively; but Jingxian found a higher percentage of total low T₃ value (47%) and a lower percentage of low T₄ (5.4%) than present study. Swaminathan study had a much higher percentage of low thyroid hormone status among all CKD patients (low T₃ 66%, low T₄ 24%).

Mean value of different Thyroid hormones of our study was T₃ (0.67 ± 0.46), T₄ (5.77 ± 2.04), TSH (6.98 ± 6.24). So here a trend of high TSH and low normal range of T₃, T₄ was found in our study though value is not significant.

Various studies have been studied by comparing CKD patients on conservative Management and patients on HD by Ramirez⁵⁰ and Kayima et al⁵¹. In uremia the mean values of T₃ & T₄ were significantly low as depicted in various international studies by Ramirez G et al⁵⁰, Lim VS et al⁵², and Pagliacci MC et al⁵³.

However, few studies showed different results, like a studies by Swaminathan et al³⁹, Rajagopalan B⁵⁴, Spector et al⁵⁵, Ramirez et al⁵⁶, Dudani et al⁵⁷, Karunanidhi et al⁵⁸ in CKD patients found that both T₃ and T₄ were significantly reduced whereas TSH remains to be unchanged in patient group compared to controls. These studies depicted abnormality in hypothalamic mechanism of TSH release in uraemic patients as the TSH response to the TRH was blunted.

Another study which was conducted by Joseph et al and Hardy et al^{36,58} revealed low T₃ T₄ level with high TSH level suggesting maintenance of pituitary thyroid axis. Low T₃ had been reported in Ramirez et al⁵⁶, Hegedus et al⁶⁰, Beckett et al⁶¹, PonAjl Singh et al⁶², P Igleasias and JJ Diez⁶³ and many others. Ramirez and Spector et al⁵⁵ study showed linear correlation between mean serum T₃ and T₄ and severity of renal failure.

- Total hypercholesterolemia is 49%. Range of cholesterol - In CKD III - 44.44%, CKD IV- 48.00% and in CKD V- 50% patients have hypercholesterolemia.
- Total hypertriglyceridemia was 25%. Range of triglyceride In CKD-III 22.2%, CKD IV-24%, CKD-V 25.8%.
- Low HDL in 84% of patients, Range 6 patients in CKD-III, 22 patients in CKD- IV, 56 patients in CKD- V.
- High LDL value in 29% of cases. Range 4 cases in CKD-III, 7 cases in CKD-IV, 18 cases in CKD-V.
- High VLDL in 54% of cases. Range 4 cases in CKD-III, 14 cases in CKD-IV, 36 cases in CKD-V.
- Mean value of cholesterol ($193.97 \pm 78.$), Triglyceride (120.58 ± 45.07), HDL (33.91 ± 6.72), LDL (83.20 ± 27.52), VLDL (31.67 ± 12.27).
- Total number of patients in Low T_3 syndrome is (13%), Low T_4 (4%), Low T_3 & Low T_4 syndrome is (5%), Subclinical hypothyroidism (15%), Overt hypothyroidism (9%), Euthyroid (59%)
- Total Low T_3 was 37 cases. In CKD III 5 cases, CKD IV 6 cases and in CKD V 26 cases.
- Total Low T_4 was 22 cases. In CKD III 2 cases, CKD IV 5 cases and in CKD V 15 cases.
- Total high TSH was 40 cases. In CKD III 5 cases, CKD IV 9 cases and in CKD V 26 cases.
- Mean T_3 , T_4 , TSH are 0.67, 5.77, 6.98

BIBLIOGRAPHY

1. Kasper D, Faucis Anthony, Hauser L Stephen, Longo L Dan, Jameson Larry J, Loscalzo Joseph, Harrison's Principles of Internal Medicine. 19th ed. of USA McGraw Hill Education. Chapter 335. Chronic kidney Disease. 1811-1833.
2. Neil Turner, Norbert Lameire, David J. Goldsmith, Christopher G. Winearls, Jonathan Himmelfarb, Giuseppe Remuzzi. Oxford Textbook of Clinical Nephrology 4th ed. Vol. 1 Oxford University Press, Section 5, Chapter 94, Chronic kidney disease: 743-754.
3. Levey, A.S., Eckardt, K.U., Tsukamoto, Y., et al. (2005). Definition and classification of chronic kidney disease: a position statement from kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*, 67, 2089-100.
4. Levey, A.S., De Jong, P.E., Coresh, J., et al. (2011). The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int*, 80, 17-28.
5. Current Chronic kidney disease (CKD) Nomenclature used by KDIGO. *Kidney international Supplements KDIGO*, 2013; Chapter 1 Definition and classification of CKD 5
6. Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J. The risk of atherosclerosis in patients with chronic kidney disease. *Int Urol nephrol*. 2013; 45(6): 1605-12.
7. Modi GK, Jha V. The incidence of end-stage renal disease in India: a population based study. *Kidney International*, 2006; 70: 2131-2133
8. Marten W. Taal, Glenn M. Chertow, Philip A. Marsden, Karl Skorecki, Alan S.L. Yu, Barry M. Brenner. Brenner & Rector's. The kidney, 9th ed. Elsevier Saunders. Chapter 81. Indian Subcontinent. 2770-2785.
9. Mani MK. The management of end-stage renal disease in India. *Artif Organs*. 1998; 22: 182-186.
10. Agarwal SK, Dash SC, Irshad M, et al. Prevalence of chronic renal failure in adults in Delhi, India. *Nephrol Dial Transplant*. 2005; 20: 1638-1642.
11. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. *Prim care*. 2008; 35(2): 329-44.
12. Atman PO, Samuelsson O, Alaupovic P. The effect of decreasing renal function on lipoprotein profiles. *Nephrol Dial Transplant*. 2011; 26(8): 2572-5.
13. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart

- Association controls on Kidney in cardiovascular disease, high blood pressure research, Clinical cardiology, and epidemiology and prevention, *Circulation*. 2003;108(17):2154-69
14. Majumder A, Wheeler DC. Lipid abnormalities in renal disease. *J R Soc Med*. 2000;93:178-182.
 15. Manttari M, Tiula E, Alikoski T, et al. Effects of hypertension and dyslipidaemia on the decline in renal function. *Hypertension*. 1995;26:670-675.
 16. Neil Turner, Norbert Lameire, David J. Goldsmith, Christopher G. Winearls, Jonathan Himmelfarb, Giuseppe Remuzzi. *Oxford Textbook of Clinical Nephrology* 4th ed. Vol. 1 Oxford University Press, Section 5, Chapter 102, Chronic kidney disease: 800.
 17. Jardine, A. G., Marik, O. M., Holdaas, H., et al. (2008). Special patient populations: chronic renal disease. In C. M. Ballantyne (ed) *Ballantyne: Clinical Lipidology*, pp. 500-508. Philadelphia, PA: Saunders.
 18. Prichard, S. S. (2003). Impact of dyslipidemia in end-stage renal disease. *J Am Soc Nephrol*, 14(9 Suppl 4), S 316-320.
 19. Monzani G, Bergesio F, Ciuti R, et al. Lipoprotein abnormalities in chronic renal failure and dialysis patients. *Blood Purif*. 1996;262-272
 20. Vaziri, N. D. (2006). Dyslipidaemia of chronic renal failure: the nature, mechanisms, and potential consequences. *Am J Physiol Renal Physiol*, 290(2), F 262-72.
 21. Marten W. Taal, Glenn M. Chertow, Philip A. Marsden, Karl Skorecki, Alan S. L. Yu, Barry M. Brenner. *Brenner & Rector's The kidney*, 9th ed. Elsevier Saunders. Chapter 51, Adaptation to Nephron Loss and mechanisms of progression in chronic kidney disease. 1952-1971.
 22. Cases A, Coll E. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. *Kidney Int Suppl*. 2005;99:S 87-S 93.
 23. Kroleswski AS, Warram JH, Christlieb AR. Hypercholesterolemia—a determinant of renal function loss and death in IDDM patients with nephropathy. *Kidney Int*. 1994;45:S125-S131.
 24. Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. *Nephrol Dial Transplant*. 1997;12:1908-1915
 25. Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. *Arch Intern Med*. 1998; 158:998-1004.
 26. Mschio G, Oldrizzi L, Raggi C, et al. Serum lipids in patients with chronic renal failure on long-term protein-restricted diets. *Am J Med*. 1989;87:51N-54N.
 27. Neil Turner, Norbert Lameire, David J. Goldsmith, Christopher G. Winearls, Jonathan Himmelfarb, Giuseppe Remuzzi. *Oxford Textbook of Clinical Nephrology* 4th ed. Vol. 1 Oxford University Press. Section 5, Chapter 132, The patient with reduced renal function: endocrinology: 1072-1090.
 28. Feinstein, E. I., Kaptein, E. M., Nicoloff, J. T., et al. (1982). Thyroid function in patients with nephrotic syndrome and normal renal function. *Am J Nephrol*, 2(2). 0-6.
 29. Malyszko J, Malyszko J, Wolczynski S, Mysliwiec M. Adiponectin, leptin and thyroid hormones in patients with chronic renal failure and on renal replacement therapy: are they related? *Nephrol Dial Transplant*. 2006;21(1):145-52.
 30. Kaptein E et al. The Thyroid in end stage renal diseases, *Medicine*, 1988;67:187-197
 31. Katz AI & Lindheimer MD. Actions of hormones on the kidney *Annual Review of Physiology* 1977; 39:97-133.
 32. Waish JD, Brenner AD, Bulsara MK, Leedman PJ, Fedima P, Micheal V. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. *Arch Intern Med* 165:2467-2472, 2005.
 33. G Avasthi, S Malhotra, APS Narag, S Sengupta: Study of thyroid function in patients of chronic renal failure. *Indian J Nephrol*, 2001;11:165-169

34. Schaeffner ESI, Kurth T, CurhanGC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM: Cholesterol and the risk of renal dysfunction in apparently healthy men. *J Am Soc Nephrol*.2003 Aug;14(8):2084-91.
35. Sahar A. H. AL-Sharqi, Enas W. SH. AL-Najar and Samal H.K. AL-Jaff: Lipid profiles and kidney function in chronic renal failure Iraqi patient preperitoneal dialysis or haemodialysis. *International Journal of Advanced Research* (2015), Volume 3, Issue 11, 776-780.
36. VeerenGanta, RadhaPriyaYalamanchi, Mahanta KC, BiswajitSahu, Kota Raghvendar, GudipatiAnusha, BharadwajBachu, C. Raghavendra Reddy, A study of lipid profile in non-diabetic chronic kidney disease, *International Journal of Advances in Medicine* 2016 Nov;3(4):965-970.
37. Chen S-C, Hung C-C, Kuo M-C, Lee J-J, Chiu Y-W, et al. (2013). Association of Dyslipidaemia with Renal Outcomes in Chronic Kidney Disease. *PLoS ONE* 8(2):e5543. doi:10.1371/journal.pone.0055643.
38. Rajapukar et al. What do we know about chronic kidney disease in India: first report of the Indian CKD registry *BMC Nephrology* 2012;13:10.
39. Modi GK I, Jha V: The incidence of end-stage renal disease in India: A population –based study. *Kidney Int*.2006 Dec;70(12):2131-3. Epub 2006 Oct 25.
40. K. Swaminathan, S. RAJESH, S. Avudaiappan. A study of thyroid function abnormalities in patients with chronic kidney disease. *Journal of Dental and Medical Sciences* e-ISSN: 2279-0853, p-ISSN: 2279-0861. Vol 15. Issue 8. Ver. VIII (Aug, 2016), PP07-15.
41. Saroj K, Rajendra KC, Sharad G. Thyroid dysfunction and dyslipidemia in chronic kidney disease patients. *Endocr Disord*.2015;15:65.
42. Poudel B, Yadav BK, Jha B, Raut KB: Dyslipidaemia in chronic kidney disease in Nepalese population. *Mymensingh Med J*. 2013 Jan;22(1):157-63.
43. Resmi Rekha Phukan, Rohini K Goswami. Unusual Dyslipidemia in Patients with Chronic Kidney disease: *Journal of Clinical and Diagnostic Research*. 2017 Jan, Vol-11(1):BC01-BC04.
44. Appel G. Lipid abnormalities in renal disease. *Kidney Intl*.1991;39(1):169-83.
45. Khalidah S. Merzah, Suhad Falih Hasson: The Biochemical Changes in Patients with Chronic Renal Failure, *International Journal of Pharma Medicine and Biological Sciences* Vol.4, N0. Januar, 2015.
46. Poudel B, Yadav BK, Jha B, Raut KB: Dyslipidaemia in chronic kidney disease in Nepalese population. *Mymensingh Med J*. 2013 Jan;22(1):157-63.
47. Raju DSSK, Lalitha DL, Kiranmayi P (2013). A study of Lipid Profile and Lipid Peroxidation in Chronic Kidney Disease with Special reference to Hemodialysis. *J Clin Res Biotech* 4:143.
48. Song SH, Kwak IS, Lee DW, Kang YH, Seong EY, Park JS. The prevalence of low triiodothyronine according to the stage of chronic kidney disease in subjects with a normal thyrotrophic stimulating hormone. *Nephrol Dial Transplant*.2009;24(5):1534-8.
49. Jingxian Fan, Peng Yan, Yingdeng Wang, Bo Shen, Feng Ding, Yingli Liu. Prevalence and clinical significance of Low T3 Syndrome in Non-Dialysis patients with Chronic Kidney Disease: *Med Sci Monit*.2016;22:1171-1179. Published online 2016 Apr 8.
50. Ramirez G et al. Thyroid abnormalities in renal failure. A study of 53 patients on chronic dialysis. *Ann Internal Medicine*, 1973;79,500-4.
51. Kayima JK et al. Thyroid hormones profile in patients with chronic renal failure on conservative management and regular haemodialysis. *East Afr Med J*, 1992;69:333-6.

52. Lim VS, Fang VS, Refetoff S. Katz AI. T3 hypothyroidism in uraemia. Impaired T4 to T3 conversion. No.636. Abstracts of 6th International Congress of Nephrology, 1975.
53. Pagliacci MC, Pelicci G. Grigani F. Giammatince FL, Carobi C, Buoncristiani U, Nicoltitti I. Thyroid function tests in patients undergoing maintenance dialysis. *Nephron* 1987;46:225-3.
54. Rajagopalan B, Dolia PB, Arumalla VK. Renal function markers and thyroid hormone status in undialyzed chronic kidney disease. *AI Ameen J Med Sci*. 2013;6(1):70-4.
55. Spector DA, Davis PJ, Helderman JH et al. Thyroid function and metabolic state in chronic renal failure. *Ann Int Med* 1976;85:724-30.
56. Ramirez G. O'Neil WM, Jubiz W. Bloomer HA. Thyroid dysfunction in uraemia. Evidence with thyroid and hypophyseal abnormalities. *Ann Int Med* 1976;84:672.
57. Dudani RA et al. Thyroid dysfunction in Ureaemia. *J Assoc Physicians India*. 1981;29:1037-40.
58. Karunanidhi A et al. Thyroid function in patient with chronic renal failure. *Indian J Med Research*. 1979;69:792-7.
59. Hardy MJ et al. Pituitary-Thyroid function in chronic renal failure assessed by a highly sensitive thyrotropin assay. *J Clin Endocrinol Metab*, 198;66:233-6.
60. Hegedus L et al. Thyroid gland volume and serum concentrations of thyroid hormone in chronic renal failure. *Nephron*, 1985;171-4.
61. Beckett G et al. Thyroid status in patient with chronic renal failure. *Clinical Nephrology*, 1983;19:172-8.
62. PonAjl Singh, Zachariah Bobby, N. Selvaraj and R. Vinayagamoorthi. Anevaluation of thyroid hormone status and oxidative stress in undialyzed chronic renal failure patients. *Indian Physiol Pharmacol* 2006;50(3):279-284.
63. Iglesias P and J Di'Ez. Thyroid dysfunction and kidney disease. *European Journal of Endocrinology* (2009)160:503-515